(Sharecast News) - Hikma Pharmaceuticals reaffirmed its full-year guidance on Thursday following a solid start to 2025, supported by stable trading across its three core divisions.
The FTSE 100 company said its injectables business delivered strong revenue growth across all geographies, with demand for recently launched products in Europe and MENA...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE